Your browser version may not work well with NCBI's Web applications. More information here...

Recent Activity

Items 1 - 20 of 115
of 6Next
1:

The safety profile of drotrecogin alfa (activated).

Fumagalli R, Mignini MA.

Crit Care. 2007;11 Suppl 5:S6. Review.

PMID: 18269693 [PubMed - indexed for MEDLINE]

2:

International integrated database for the evaluation of severe sepsis (INDEPTH): clinical evaluation committee report on the safety of drotrecogin alfa (activated) therapy.

Dhainaut JF; INDEPTH Clinical Evaluation Committee.

Curr Med Res Opin. 2008 Apr;24(4):1187-97. Epub 2008 Mar 17.

PMID: 18348744 [PubMed - indexed for MEDLINE]

3:

Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis.

Barie PS, Hydo LJ, Shou J, Eachempati SR.

Surg Infect (Larchmt). 2006;7 Suppl 2:S77-80. Review.

PMID: 16895513 [PubMed - indexed for MEDLINE]

4:

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, McL Booth FV.

Surgery. 2006 Nov;140(5):726-39. Corrected and republished in: Surgery. 2007 Apr;141(4):548-61.

PMID: 17084715 [PubMed - indexed for MEDLINE]

5:

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort.

Payen D, Sablotzki A, Barie PS, Ramsay G, Lowry S, Williams M, Sarwat S, Northrup J, Toland P, Booth FV.

Surgery. 2007 Apr;141(4):548-61.

PMID: 17431957 [PubMed - indexed for MEDLINE]

6:

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis.

Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL.

Crit Care. 2003 Apr;7(2):155-63. Epub 2003 Feb 28. Review.

PMID: 12720562 [PubMed - indexed for MEDLINE]

7:

Safety of drotrecogin alfa (activated) in the treatment of patients with severe sepsis.

McCoy C.

Expert Opin Drug Saf. 2004 Nov;3(6):625-37. Review.

PMID: 15500421 [PubMed - indexed for MEDLINE]

8:

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Trzaskoma BL, François B, Guy JS, Brückmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL; Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.

N Engl J Med. 2005 Sep 29;353(13):1332-41.

PMID: 16192478 [PubMed - indexed for MEDLINE]

9:

International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.

Laterre PF, Nelson DR, Macias W, Abraham E, Sashegyi A, Williams MD, Levy M, Levi M, Utterback B, Vincent JL.

J Crit Care. 2007 Jun;22(2):142-52. Epub 2007 Jan 31.

PMID: 17548026 [PubMed - indexed for MEDLINE]

10:

Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated).

Levi M, Levy M, Williams MD, Douglas I, Artigas A, Antonelli M, Wyncoll D, Janes J, Booth FV, Wang D, Sundin DP, Macias WL; Xigris and Prophylactic HepaRin Evaluation in Severe Sepsis (XPRESS) Study Group.

Am J Respir Crit Care Med. 2007 Sep 1;176(5):483-90. Epub 2007 Jun 7.

PMID: 17556722 [PubMed - indexed for MEDLINE]

11:

Clinical trials in severe sepsis with drotrecogin alfa (activated).

Laterre PF.

Crit Care. 2007;11 Suppl 5:S5. Review.

PMID: 18269692 [PubMed - indexed for MEDLINE]

12:

From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated).

Short MA, Schlichting D, Qualy RL.

Curr Med Res Opin. 2006 Dec;22(12):2525-40. Review.

PMID: 17265595 [PubMed - indexed for MEDLINE]

13:

Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.

Bernard GR, Margolis BD, Shanies HM, Ely EW, Wheeler AP, Levy H, Wong K, Wright TJ; Extended Evaluation of Recombinant Human Activated Protein C United States Investigators.

Chest. 2004 Jun;125(6):2206-16.

PMID: 15189943 [PubMed - indexed for MEDLINE]

14:

Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.

[No authors listed]

Prescrire Int. 2007 Feb;16(87):7-9.

PMID: 17323514 [PubMed - indexed for MEDLINE]

15:

Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.

Ely EW, Laterre PF, Angus DC, Helterbrand JD, Levy H, Dhainaut JF, Vincent JL, Macias WL, Bernard GR; PROWESS Investigators.

Crit Care Med. 2003 Jan;31(1):12-9.

PMID: 12544987 [PubMed - indexed for MEDLINE]

16:

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

Nadel S, Goldstein B, Williams MD, Dalton H, Peters M, Macias WL, Abd-Allah SA, Levy H, Angle R, Wang D, Sundin DP, Giroir B; REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group.

Lancet. 2007 Mar 10;369(9564):836-43.

PMID: 17350452 [PubMed - indexed for MEDLINE]

17:

A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial.

Wheeler A, Steingrub J, Schmidt GA, Sanchez P, Jacobi J, Linde-Zwirble W, Bates B, Qualy RL, Woodward B, Zeckel M.

Crit Care Med. 2008 Jan;36(1):14-23.

PMID: 18158435 [PubMed - indexed for MEDLINE]

18:

Safety of drotrecogin alfa (activated) in surgical patients with severe sepsis.

Fry DE, Beilman G, Johnson S, Williams MD, Rodman G, Booth FV, Bates BM, McCollam JS, Lowry SF; PROWESS Surgical Evaluation Committee.

Surg Infect (Larchmt). 2004 Fall;5(3):253-9.

PMID: 15684796 [PubMed - indexed for MEDLINE]

19:

The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.

Angus DC, Laterre PF, Helterbrand J, Ely EW, Ball DE, Garg R, Weissfeld LA, Bernard GR; PROWESS Investigators.

Crit Care Med. 2004 Nov;32(11):2199-206.

PMID: 15640631 [PubMed - indexed for MEDLINE]

20:

Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.

De Backer D.

Drug Saf. 2007;30(11):995-1010. Review.

PMID: 17973539 [PubMed - indexed for MEDLINE]

Items 1 - 20 of 115
of 6Next